April 20, 2018 / 6:58 PM / 5 months ago

BRIEF-Lilly Reports Additional Top-Line Results From Cyramza Phase 3 Range Study

April 20 (Reuters) - Eli Lilly and Co:

* LILLY REPORTS ADDITIONAL TOP-LINE RESULTS FROM CYRAMZA® (RAMUCIRUMAB) PHASE 3 RANGE STUDY IN ADVANCED OR METASTATIC UROTHELIAL CANCER

* SAYS SIGNIFICANT IMPROVEMENT IN PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL PREVIOUSLY REPORTED

* SAYS IMPROVEMENT IN OBJECTIVE RESPONSE RATE OBSERVED

* SAYS POSITIVE TREND IN OVERALL SURVIVAL DID NOT REACH STATISTICAL SIGNIFICANCE

* SAYS NO NEW SAFETY SIGNALS WERE OBSERVED

* SAYS POSITIVE TREND WAS SEEN IN SECONDARY ENDPOINT OF OVERALL SURVIVAL WHICH DID NOT REACH STATISTICAL SIGNIFICANCE

* SAYS SAFETY PROFILE OBSERVED IN RANGE STUDY CONSISTENT WITH WHAT WAS SEEN PREVIOUSLY IN TRIAL & HAS BEEN PREVIOUSLY OBSERVED FOR CYRAMZA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below